NCT06237491View on ClinicalTrials.gov

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

November 7, 2025

Study Completion Date

December 17, 2025

Conditions
Metastatic Castration-resistant Prostate Cancer, mCRPC
Interventions
DRUG

177Lu-LNC1003 Injection group 1

The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.

DRUG

177Lu-LNC1003 Injection group 2

The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.

DRUG

177Lu-LNC1003 Injection group 3

The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.

All Listed Sponsors
lead

Yantai LNC Biotechnology Singapore PTE. LTD.

INDUSTRY